At Takeda, we exist to create better health for people and a brighter future for the world. Our global team of researchers and scientists harness cutting-edge science to push the boundaries of what is possible. We focus our R&D efforts on four therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases, and make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

R&D AUSTRIA

R&D AUSTRIA is a central player in Takeda’s global R&D engine. Our R&D activities in Austria cover the entire pharmaceutical development process from the selection of a product candidate over the monitoring of clinical trials up to the market release of the product.

- We are focused on addressing high unmet medical need across our core therapeutic areas
- We enable product candidates, develop & improve manufacturing processes to support clinical trials and market approval
- We developed 10+ medicines*
- We are 200+ employees
- We are acknowledged experts in recombinant biologics, and process development 5.0 platforms
- We provide solutions to process and product related challenges in a fast-paced, highly professional environment
- Medicines we develop are exported to 100+ countries worldwide
- We do cutting-edge research, publish in renown journals and successfully file for patents

*Administered after regulatory approval and/or in any stage of clinical development
WE SEEK INNOVATION AND PARTNER TO NURTURE IT, WHEREVER IT RESIDES

We work with partners to create complementary collaborations where our global reach, scientific expertise and clinical excellence can help them bring their scientific innovation and vision to patients. Our partners include academia, start-ups, research institutes, health care providers, student & alumni networks.

“...We want to be THE recognized and well-known partner of choice when working with academia/start-ups in the field of product development and technology innovation in Europe.”

Dr. Manfred Rieger
Site Head R&D Austria

OUR NEW R&D AUSTRIA FACILITY

A new, state-of-the-art lab and office building in Vienna will become the main office of R&D Austria (planned opening date is 2026). This ‘Lab of the Future’ will be environmentally friendly, accessible, and modular, meeting the needs of a modern R&D organization. It will be equipped with high-end infrastructure to develop innovative technologies using robotics, augmented reality, artificial intelligence, and simulations of processes using digital twins.

+250 EMPLOYEES

~25,000 m²

GREEN BUILDING

RnD.Austria@takeda.com
www.takeda.com